JP2023076632A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023076632A5 JP2023076632A5 JP2023061284A JP2023061284A JP2023076632A5 JP 2023076632 A5 JP2023076632 A5 JP 2023076632A5 JP 2023061284 A JP2023061284 A JP 2023061284A JP 2023061284 A JP2023061284 A JP 2023061284A JP 2023076632 A5 JP2023076632 A5 JP 2023076632A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrosis
- amino
- therapeutic agent
- agent according
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010016654 Fibrosis Diseases 0.000 claims 14
- 230000004761 fibrosis Effects 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims 7
- ORRNXRYWGDUDOG-UHFFFAOYSA-N 4-[2-fluoro-4-[(2-phenylacetyl)carbamothioylamino]phenoxy]-7-methoxy-n-methylquinoline-6-carboxamide Chemical compound C1=CN=C2C=C(OC)C(C(=O)NC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=S)NC(=O)CC1=CC=CC=C1 ORRNXRYWGDUDOG-UHFFFAOYSA-N 0.000 claims 4
- 201000002793 renal fibrosis Diseases 0.000 claims 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 206010028537 myelofibrosis Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010019837 Hepatocellular injury Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 231100000437 hepatocellular injury Toxicity 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015127788 | 2015-06-25 | ||
| JP2015127788 | 2015-06-25 | ||
| PCT/JP2016/068902 WO2016208744A1 (ja) | 2015-06-25 | 2016-06-24 | 線維症治療剤 |
| JP2017525457A JP6974167B2 (ja) | 2015-06-25 | 2016-06-24 | 線維症治療剤 |
| JP2021180108A JP7258985B2 (ja) | 2015-06-25 | 2021-11-04 | 線維症治療剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021180108A Division JP7258985B2 (ja) | 2015-06-25 | 2021-11-04 | 線維症治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023076632A JP2023076632A (ja) | 2023-06-01 |
| JP2023076632A5 true JP2023076632A5 (enrdf_load_html_response) | 2023-07-07 |
| JP7498827B2 JP7498827B2 (ja) | 2024-06-12 |
Family
ID=57585165
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525457A Active JP6974167B2 (ja) | 2015-06-25 | 2016-06-24 | 線維症治療剤 |
| JP2021180108A Active JP7258985B2 (ja) | 2015-06-25 | 2021-11-04 | 線維症治療剤 |
| JP2023061284A Active JP7498827B2 (ja) | 2015-06-25 | 2023-04-05 | 線維症治療剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525457A Active JP6974167B2 (ja) | 2015-06-25 | 2016-06-24 | 線維症治療剤 |
| JP2021180108A Active JP7258985B2 (ja) | 2015-06-25 | 2021-11-04 | 線維症治療剤 |
Country Status (20)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8324454B2 (en) | 2006-03-14 | 2012-12-04 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| US12152246B2 (en) | 2006-03-14 | 2024-11-26 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| PT3583943T (pt) | 2017-02-15 | 2024-10-15 | Taiho Pharmaceutical Co Ltd | Composição farmacêutica |
| EP3682882A4 (en) | 2017-09-08 | 2021-06-02 | Taiho Pharmaceutical Co., Ltd. | ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER |
| MA53667A (fr) | 2018-09-18 | 2021-07-28 | Taiho Pharmaceutical Co Ltd | Polythérapie associant un composé d'acylthiourée et de l'abiratérone |
| TWI872203B (zh) * | 2020-02-14 | 2025-02-11 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
| CN115177636A (zh) * | 2022-07-18 | 2022-10-14 | 陕西科美致尚生物科技有限公司 | 一种用于治疗前列腺钙化的组合物及其制备方法与应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69939586D1 (de) | 1998-04-28 | 2008-10-30 | Toshikazu Nakamura | Inhibitoren für die gefässneubildung |
| JP2003238592A (ja) | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| AU2006265835B2 (en) | 2005-06-30 | 2012-05-03 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
| CN101360748B (zh) * | 2005-11-30 | 2012-05-30 | 沃泰克斯药物股份有限公司 | c-MET抑制剂及其应用 |
| MX2008007049A (es) | 2005-11-30 | 2008-10-23 | Vertex Pharma | Inhibidores de c-met y usos de los mismos. |
| JP2010519204A (ja) | 2007-02-16 | 2010-06-03 | アムジエン・インコーポレーテツド | 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用 |
| ATE523508T1 (de) | 2007-10-25 | 2011-09-15 | Astrazeneca Ab | Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate |
| CN101998951B (zh) * | 2008-04-10 | 2013-07-17 | 大鹏药品工业株式会社 | 酰基硫脲化合物或其盐及其用途 |
| UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| BR112012019302B1 (pt) | 2010-02-03 | 2022-06-21 | Incyte Holdings Corporation | Imidazo[1,2-b] [1,2,4]triazinas como inibidores de c-met, composição que as compreende e métodos in vitro de inibir a atividade de c-met cinase, de inibir a via de sinalização da hgf/c-met cinase em uma célula e de inibir a atividade proliferativa de uma célula |
| DK2571878T3 (en) | 2010-05-17 | 2019-02-11 | Indian Incozen Therapeutics Pvt Ltd | Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| RU2494470C1 (ru) * | 2012-04-04 | 2013-09-27 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") | Способ лечения фиброза легких |
| US9149471B2 (en) | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
-
2016
- 2016-06-24 DK DK16814513.4T patent/DK3315131T3/da active
- 2016-06-24 KR KR1020177033481A patent/KR102647942B1/ko active Active
- 2016-06-24 MA MA042266A patent/MA42266A/fr unknown
- 2016-06-24 SG SG11201709260TA patent/SG11201709260TA/en unknown
- 2016-06-24 ES ES16814513T patent/ES2928684T3/es active Active
- 2016-06-24 WO PCT/JP2016/068902 patent/WO2016208744A1/ja not_active Ceased
- 2016-06-24 HU HUE16814513A patent/HUE060732T2/hu unknown
- 2016-06-24 MX MX2017016774A patent/MX381792B/es unknown
- 2016-06-24 CA CA2990791A patent/CA2990791A1/en active Pending
- 2016-06-24 PH PH1/2017/502322A patent/PH12017502322B1/en unknown
- 2016-06-24 PL PL16814513.4T patent/PL3315131T3/pl unknown
- 2016-06-24 US US15/574,060 patent/US10449189B2/en active Active
- 2016-06-24 JP JP2017525457A patent/JP6974167B2/ja active Active
- 2016-06-24 CN CN202110067291.6A patent/CN112716952A/zh active Pending
- 2016-06-24 RU RU2017145271A patent/RU2729630C2/ru active
- 2016-06-24 AU AU2016284531A patent/AU2016284531B2/en active Active
- 2016-06-24 EP EP21205221.1A patent/EP3973962A1/en not_active Withdrawn
- 2016-06-24 EP EP16814513.4A patent/EP3315131B1/en active Active
- 2016-06-24 PT PT168145134T patent/PT3315131T/pt unknown
- 2016-06-24 MY MYPI2017704204A patent/MY191219A/en unknown
- 2016-06-24 BR BR112017028137-6A patent/BR112017028137B1/pt active IP Right Grant
- 2016-06-24 CN CN201680037175.7A patent/CN107708697B/zh active Active
- 2016-06-24 SG SG10201912684TA patent/SG10201912684TA/en unknown
-
2017
- 2017-12-19 MX MX2020012989A patent/MX2020012989A/es unknown
-
2019
- 2019-09-17 US US16/573,362 patent/US10695340B2/en active Active
-
2020
- 2020-06-02 US US16/889,870 patent/US11191759B2/en active Active
-
2021
- 2021-10-29 US US17/513,946 patent/US11690838B2/en active Active
- 2021-11-04 JP JP2021180108A patent/JP7258985B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061284A patent/JP7498827B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023076632A5 (enrdf_load_html_response) | ||
| JP5557169B2 (ja) | ナテグリニド含有製剤 | |
| RU2003127750A (ru) | 4-фтор-n-индан-2-илбензамид и его применение в качестве фармацевтического агента | |
| JP5769763B2 (ja) | 治療用組成物およびその使用 | |
| JP2019059760A5 (enrdf_load_html_response) | ||
| JP2009517411A5 (enrdf_load_html_response) | ||
| JP2002519318A5 (enrdf_load_html_response) | ||
| JP2007511487A5 (enrdf_load_html_response) | ||
| RU2008148547A (ru) | Фармацевтические композиции, включающие дулоксетина гидрохлорид с замедленным высвобождением | |
| CY1108360T1 (el) | Φαρμακο που περιεχει εναν πολυ ισχυρο, βητα-2-ανταγωνιστη μακρας διαρκειας σε συνδυασμο με αλλα δραστικα συστατικα | |
| CA2671470A1 (en) | Powder formulation for valganciclovir | |
| JP2002528502A5 (enrdf_load_html_response) | ||
| JP2023057082A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
| JPWO2023054732A5 (enrdf_load_html_response) | ||
| JP2004532828A5 (enrdf_load_html_response) | ||
| RU2007143087A (ru) | Композиция с модифицированным высвобождением минимум одной формы венлафаксина | |
| JP2005511724A (ja) | 鼻炎を処置するためのｈ１アンタゴニストおよび安全なステロイドの使用 | |
| JP2019510834A5 (enrdf_load_html_response) | ||
| JP2006524190A5 (enrdf_load_html_response) | ||
| JPH10513186A (ja) | Ｈｉｖプロテアーゼ阻害剤インジナビル及び逆転写酵素阻害剤３ｔｃを必要に応じてａｚｔ、ｄｄｉ、又はｄｄｃと共に用いるｈｉｖ感染の組合せ治療 | |
| JP5386478B2 (ja) | パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用 | |
| JP2007524699A5 (enrdf_load_html_response) | ||
| JPWO2021110805A5 (enrdf_load_html_response) | ||
| EA199900226A1 (ru) | Фармацевтические композиции для лечения вирусных заболеваний | |
| RU2005119970A (ru) | Оптически активное производное дигидропиридина |